MET and non-small cell lung carcinoma: Furthermore, we design a PTPN23 peptide that competes with endogenous PTPN23 for binding WDR4 and demonstrate its efficacies in stabilizing PTPN23, promoting the degradation of EGFR, EGFR mutant, and c-MET, and suppressing the growth and progression of EGFR TKI-resistant NSCLC.